



BRUST-ZENTRUM ZÜRICH

CURRICULUM VITAE

Prof. Dr. med. Uwe Güth

Facharzt Gynäkologie und Geburtshilfe

Sprachen

Deutsch, Englisch

Kontakt

uwe.gueth@brust-zentrum.ch

T +41 44 533 81 14

Beruflicher Werdegang

Seit 11.2015	Senior Consultant, Brust-Zentrum Zürich AG, Koordinator des zertifizierten Brustkrebszentrums der Hirslandenklinik Zürich (DKG), Leiter Brust-Zentrum Zürich West.
09.2011 – 10.2015	Leitender Arzt, Chefarzt Gynäkoonkologie / Leiter des zertifizierten Brust- Zentrums (SGS/KLS), Kantonsspital Winterthur
02.2010 – 08.2011	Oberarzt Frauenklinik, Universitätsspital Basel
03.2009 – 12.2009	Oberarzt Gynaecological Cancer Centre, University London College Hospital (UCLH)
08.2001 – 02.2009	Oberarzt Frauenklinik, Universitätsspital Basel
2000 – 2001	Oberarzt Frauenklinik Akademisches Lehrkrankenhaus der Universität Göttingen, Klinikum Wolfsburg
2000	Oberarzt Frauenklinik Akademisches Lehrkrankenhaus der Universität Düsseldorf, Bethesda Krankenhaus Duisburg

Ausbildung

07.2014	Diplom Senologie (SGGG)
2012	Ernennung zum Titularprofessor durch die Regenz der Universität Basel



09.2011	Schwerpunkttitel Gynäko-Onkologie durch die European Society for Gynecologic Oncology (ESGO)
2009	Erteilung der Lehrbefugnis und Ernennung zum Privatdozenten durch die Medizinische Fakultät der Universität Basel
1999	Facharzt für Frauenheilkunde und Geburtshilfe
1996 – 1999	Akademisches Lehrkrankenhaus der Medizinischen Hochschule Hannover Frauenklinik, Klinikum Minden
1995	Promotion, Heinrich-Heine-Universität Düsseldorf
1994 – 1995	Akademisches Lehrkrankenhaus der Universität Düsseldorf Frauenklinik, Klinikum Krefeld
1994	Abt. für Gynäkologie und Geburtshilfe, Johanniter Krankenhaus Rheinhausen
1987 – 1994	Studium der Humanmedizin, Heinrich-Heine-Universität Düsseldorf
1985 – 1987	Zivildienst, St. Elisabeth Hospital Gütersloh (OP-Helfer)
1985	Abitur, Städtisches Gymnasium Gütersloh

Publikationen

Bei den Publikationen in Fachzeitschriften, die im Science Citation Index gelistet sind, wird der Thomson Reuters Impact Factor (IF) des jeweiligen Erscheinungsjahres angegeben.

1. **Güth U.**, Tsakiris DA., Reber A., Holzgreve W., Hösli I.; *Sub- und postpartales Management von Patientinnen mit von-Willebrand-Jürgens-Syndrom Typ 2B*. Z Geburtsh Neonat 2002; 206: 151-55. [IF: 0.380].
2. **Güth U.**, Breinbauer S., Ernst C., Sutter J., Surbek DV., Humburg J., Sartorius G., Holzgreve W.; *Elektronische Erfassung und Abrechnung ambulanter ärztlicher Leistungen mit simultanem Vergleich zweier Tarifstrukturen (SLK/TARMED) in der Universitäts-Frauenklinik Basel*. Schweizerische Ärztezeitung 2003; 84 (4): 148-156.
3. **Güth U.**, Schiesser M., Kaiser C., Bruder E., Tercanli S., Wight E., Holzgreve W.; *Sonographie – das wegweisende bildgebende Verfahren zur Erkennung der diabetischen Mastopathie*. Gynäkol Prax 2003; 27: 85-92.
4. **Güth U.**, Schiesser M., Kaiser C., Bruder E., Tercanli S., Wight E., Holzgreve W.; *Diabetische Mastopathie: über Mosaiksteine zur Diagnose und adäquaten Behandlung*. Internist Prax 2003; 43: 741-48.
5. Lapaire O., Rudin C., **Güth U.**, Holzgreve W., Hösli I.; *Human Immunodeficiency Virus (HIV): Aktuelles aus der Geburtshilfe*. Pädiat Prax 2003; 64: 603-13.
6. Lapaire O., **Güth U.**, Holzgreve W., Hösli I.; *Fetale Pulsoxymetrie: Akzeptanz der Mutter und des geburtshilflichen Teams*. Geburtsh Frauenheilk 2003; 63: 140-44. [IF: 0.726].
7. **Güth U.**, Moch H., Dellas S., Wight E., Holzgreve W.; *Detektion kleinster Mammakarzinome- Gefahr der Übertherapie*. Geburtsh Frauenheilk 2003; 63: 1131-36. [IF: 0.726].
8. **Güth U.**, Moch H., Herberich L., Holzgreve W.; *Noninflammatory breast carcinoma with skin involvement: clinical diagnosis is relevant to appropriate classification in TNM system*. Cancer 2004; 100: 470-478. [IF: 4.434].



9. **Güth U.**, Wight E., Moch H., Holzgreve W.; *Detection of minute breast cancers: A therapeutic challenge with a potential danger of overtreatment.* Breast J 2004; 10: 373-74. [IF: 1.610].
10. **Güth U.**, Wight E., Schötzau A., Langer I., Dieterich H., Rochlitz C., Herberich L., Holzgreve W., Singer G.; *Breast carcinoma with noninflammatory skin involvement (T4b) - time to abandon a historical relic from the TNM Classification.* Cancer 2005; 104: 1862-1870. [IF: 4.800].
11. **Güth U.**, Singer G., Schötzau A., Langer I., Dieterich H., Rochlitz C., Herberich L., Holzgreve W., Wight E.; *Scope and significance of nonuniform classification practices in breast cancer with noninflammatory skin involvement: a clinicopathologic study and an international survey.* Ann Oncol 2005; 16: 1618-23. [IF: 4.935].
12. **Güth U.**, Wight E., Schötzau A., Langer I., Dieterich H., Rochlitz C., Herberich L., Holzgreve W., Mihatsch M.J., Singer G.; *Correlation and significance of histopathological and clinical features in breast cancer with skin involvement (T4b).* Hum Pathol 2006; 37: 264-71. [IF: 2.810].
13. **Güth U.**, Wight E., Langer I., Schötzau A., Dieterich H., Herberich L., Holzgreve W., Singer G.; *Breast cancer sagittal/horizontal plane location influences axillary lymph node involvement.* Eur J Surg Oncol 2006; 32: 287-91. [IF: 1.873].
14. **Güth U.**, Singer G., Langer I., Schötzau A., Herberich L., Holzgreve W., Wight E.; *T4 category revision enhances accuracy and significance of stage III breast cancer.* Cancer 2006; 106: 2569-75 [IF: 4.582].
15. Stadlmann S.*; **Güth U.*** (*authors contributed equally to the work), Reiser U., Diener P., Zeimet A., Wight E., Mirlacher M., Sauter G., Mihatsch M.J., Singer G.; *Epithelial growth factor receptor (EGFR) status in primary and recurrent ovarian cancer.* Mod Pathol 2006; 19: 607-10. [IF: 3.753].
16. **Güth U.**, Wight E., Schötzau A., Langer I., Dieterich H., Rochlitz C., Herberich L., Holzgreve W., Singer G.; *A new approach in breast cancer with noninflammatory skin involvement.* Acta Oncol 2006; 45: 576-83. [IF: 1.856].
17. **Güth U.**, Wight E., Singer G.; *Mammakarzinome mit nichtinflammatorischer Hautbeteiligung: Neue Daten revidieren das traditionelle Bild einer „klassischen“ kliniko-pathologischen Entität.* Schweiz Rundsch Medizin Prax 2006; 95: 1489-95.
18. **Güth U.**, Wight E., Schötzau A., Langer I., Dieterich H., Rochlitz C., Herberich L., Holzgreve W., Singer G.; *Noninflammatory skin involvement in breast cancer, histologically proven but without the clinical and histological T4 category features.* J Surg Oncol 2007; 95: 291-97. [IF: 2.384].
19. **Güth U.**, Singer G.; *Ektopes Prostatagewebe in der Zervix uteri.* Pathologe 2007; 28: 291-93. [IF: 0.487].
20. **Güth U.**, Renner R., Egelhof T., Singer G., Holzgreve W., Mayr J.; *Retroperitoneal placement of ovary and fallopian tube: a rare complication of surgical management of incarcerated inguinal hernia in infant girls.* J Pediatr Surg 2007; 42: e33-e35. [IF: 1.227].
21. Willi B., Steinke K., **Güth U.**; *Späte Schwangerschaft? Das klarzellige Ovarialkarzinom in der Differenzialdiagnose grosser intraabdominaler Tumoren.* RoFo; 2007; 179: 179-80. [IF: 1.882].
22. Stadlmann S., **Güth U.*** (*authors contributed equally to the work), Wight E., Kunz-Schughardt L., Hartmann A., Singer G.*; *Expression of peroxisome proliferator activated receptor-gamma and cyclooxygenase-2 in primary and recurrent ovarian carcinoma.* J Clin Pathol 2007; 60: 307-10. [IF: 2.426].
23. Stadlmann S., **Güth U.**, Baumhör D., Moch H., Terraciano L., Singer G.; *Glypican 3 expression in primary and recurrent ovarian carcinomas.* Int J Gynecol Pathol 2007; 26: 341-44. [IF: 1.748].
24. **Güth U.**, Huang DJ., Bauer G., Stieger M., Wight E., Singer G.; *Metastatic patterns at autopsy in patients with ovarian carcinoma.* Cancer 2007; 110: 1272-80. [IF: 4.632].
25. **Güth U.**, Huang DJ., Holzgreve W., Wight E., Singer G.; *T4 breast cancer under closer inspection: A case for revision of the TNM Classification.* Breast 2007; 16: 625-36. [IF: 2.155].



26. Eisenbrand M.C., Wight E., **Güth U.**, Zanetti-Dällenbach R.; *Schwangerschaftsassoziertes Mammarkarzinom*. Therapeutische Umschau 2008; 65: 223-229.
27. Stadlmann S., Dirnhofer S., **Güth U.**, Thies S., Singer G. ERCC1-immunoexpression does not predict platinum-resistance in ovarian cancer. *Gynecol Oncol* 2008; 108: 252-53. [IF: 2.919].
28. **Güth U.**, Huang D.J., Huber M., Schötzau A., Wruk D., Holzgreve W., Wight E., Zanetti-Dällenbach R.; *Tumor size and detection in breast cancer: Self-examination and clinical breast examination are at their limit*. *Cancer Detect Prev* 2008; 32: 224-228. [IF: 1.951].
29. **Güth U.**, Huang D.J., Schötzau A., Zanetti-Dällenbach R., Holzgreve W., Bitzer J., Wight E.; *Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer*. *Br J Cancer* 2008; 99: 428-33. [IF: 4.846].
30. Zanetti-Dällenbach R., **Güth U.**, Lapaire O.; *Mamma- und gynäkologische Karzinome in der Schwangerschaft*. *Frauenheilkunde up2date* 2008; 2 (6): 489-505.
31. Zanetti-Dällenbach R., Krause E.M., Lapaire O., **Güth U.**, Holzgreve W., Wight E.; *Impact of hormone replacement therapy on the histologic subtype of breast cancer*. *Arch Gynecol Obstet* 2008; 278: 443-449. [IF: 0.727].
32. Viale G., Giobbie-Hurder A., Regan M.M., Coates A.S., Mastropasqua M.G., Dell'Orto P., Maiorano E., MacGrogan G., Braye S.G., Ohlschlegel C., Neven P., Orosz Z., Olszewski W.P., Knox F., Thürlimann B., Price K.N., Castiglione-Gertsch M., Gelber R.D., Gusterson B.A., Goldhirsch A.; Breast International Group Trial 1-98. *Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole*. *J Clin Oncol* 2008; 26: 5569-75. [IF: 17.157].
33. Wyler S., Huang DJ., Singer G., Schötzau A., Holzgreve W., **Güth U.**; *Metastatic involvement of the urinary tract in patients with advanced ovarian carcinoma: Lessons from the autopsy for an interdisciplinary treatment approach*. *Eur J Gynaecol Oncol* 2009; 30:174-77. [IF: 0.641].
34. **Güth U.**, Brenckle D., Huang DJ., Schötzau A., Viehl CT., Dieterich H., Holzgreve W., Wight E., Singer G.; *Three-dimensional pathological size assessment in primary breast carcinoma*. *Breast Cancer Res Treat* 2009; 116: 257-62. [IF: 4.696].
35. **Güth U.**, Huang D.J., Schötzau A., Holzgreve W., Wight E.; *Systemic therapy of metastatic breast cancer: The truth beyond the clinical trials*. *Oncology* 2009; 76: 247-53. [IF: 2.112].
36. **Güth U.**, Huang D.J., Dirnhofer S., Rochlitz C., Wight E.; *Distant metastatic breast cancer as an incurable disease: A tenet with a need for revision*. *Cancer J* 2009; 15: 81-86. [IF: 3.471].
37. Giobbie-Hurder A., Price K.N., Gelber R.D.; International Breast Cancer Study Group; BIG 1-98 Collaborative Group. *Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer*. *Clin Trials* 2009; 6: 272-87. [IF: 1.917].
38. BIG 1-98 Collaborative Group, Mouridsen H., Giobbie-Hurder A., Goldhirsch A., Thürlimann B., Paridaens R., Smith I., Mauriac L., Forbes J.F., Price K.N., Regan M.M., Gelber R.D., Coates A.S.; *Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer*. *N Engl J Med* 2009; 361: 766-76. [IF: 47.050].
39. Rabaglio M., Sun Z., Price K.N., Castiglione-Gertsch M., Hawle H., Thürlimann B., Mouridsen H., Campone M., Forbes J.F., Paridaens R.J., Colleoni M., Pienkowski T., Nogaret J.M., Läng I., Smith I., Gelber R.D., Goldhirsch A., Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups. *Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial*. *Ann Oncol* 2009; 20: 1489-98. [IF: 5.647].



40. **Güth U.**, Kann S.R., Huang D.J., Schötzau A., Holzgreve W., Wight E.; *Systemic therapy developments and their effects regarding the current concept of recurrent ovarian carcinoma as a chronic disease.* Arch Gynecol Obstet 2009; 280: 719-724. [IF: 0.912].
41. **Güth U.**, Huang D.J., Schötzau A., Singer G., Dirnhofner S., Wight E.; *Breast cancer with non-inflammatory skin involvement: Current data on an underreported entity and its problematic classification.* Breast 2010; 19: 59-64. [IF: 2.089].
42. **Güth U.**, Huang D.J., Schötzau A., Wight E.; *Is the current concept of recurrent ovarian carcinoma as a chronic disease also applicable in platinum resistant patients?* Arch Gynecol Obstet 2010; 281: 339-344. [IF: 1.072].
43. **Güth U.**, Ella W.A., Olaitan A., Hadwin R.J., Arora R., McCormack M.; *Total vaginal necrosis: a representative example of underreporting severe late toxic reaction after concomitant chemoradiation for cervical cancer.* Int J Gynecol Cancer 2010; 20: 54-60. [IF: 1.558].
44. **Güth U.**, Kilic N., Schmid S.; *Das Konzept der chronischen Erkrankung in der Palliativbehandlung onkologischer Patientinnen: Schweizer Daten und Fakten zu Mamma- und Ovarialkarzinom.* Schweiz Rundsch Medizin Prax 2010; 99: 1413-21.
45. Tsepov D., **Güth U.**, Hadwin R.J.; *Treatment related morbidity in cervical cancer patients.* Current Women's Health Reviews 2011; 7: 87-93.
46. Schmid S.M., Lapaire O., Huang D.J., Jürgens F.E., **Güth U.**; *Cannabinoid hyperemesis syndrome: an underreported entity causing nausea and vomiting in pregnancy.* Arch Gynecol Obstet 2011; 284: 1095-97. [IF: 1.277].
47. Tapia C., Zlobec I., Schneider S., Kilic E., **Güth U.**, Bubendorf Kim S.; *Deletion of the ING4 tumor suppressor gene is prevalent in HER-2-positive breast cancer.* Hum Pathol 2011; 42: 983-90. [IF: 2.876].
48. Schmid S.M., Myrick M.E., Forrer F., Obermann E.C., Viehl C.T., Rochlitz C., **Güth U.**; *Sentinel lymph node biopsy in primary breast cancer: Trust the radiolabeled colloid method and avoid unnecessary procedures.* Eur J Surg Oncol 2011; 37: 211-16. [IF: 2.499].
49. **Güth U.**, Müller D., Huang D.J., Obermann E., Müller H.J.; *Strictly defined male breast cancer.* Familial Cancer 2011; 10: 73-77. [IF: 2.139].
50. Schmid S.M., Modlasiak A.M., Myrick M.E., Kilic N., Viehl C.T., Schötzau A., **Güth U.**; *Success and failure of primary medical, nonoperative management in breast cancer.* Ann Surg Oncol 2011; 18: 2166-72. [IF: 4.166].
51. **Güth U.**, Sartorius G., Obermann E.D.; *Tubargravidität nach erfolgreicher Methotrexattherapie.* Pathologe 2011; 32: 514-16. [IF: 0.669].
52. Schmid S.M., Pfefferkorn C., Myrick M.E., Viehl C.T., Obermann E., Schötzau A., **Güth U.**; *Prognosis of early stage synchronous bilateral cancer.* Eur J Surg Oncol 2011; 37: 623-628. [IF: 2.499].
53. **Güth U.**, Myrick M.E., Reisch T., Bosshard G., Schmid S.; *Suicide in breast cancer: an individual-centered approach provides insight beyond epidemiology.* Acta Oncologica 2011; 50: 1037-44. [IF: 3.330].
54. Huober J., Baumann M., Rochlitz C., Aebi S., **Güth U.**, von Moos R., Müller A., von Rohr L., Widmer I., Thürlimann B.; *Trastuzumab treatment beyond progression in advanced breast cancer: patterns if care in six Swiss breast cancer centres.* Oncology 2011; 81: 160-166. [IF: 2.267].
55. Moffat R.M., Eichholzer M., Myrick M.E., Schmid S.M., Raggi A., de Geyter C., Schötzau A., **Güth U.**; *Menopausal state in breast cancer: how reliable is the data?* Clinical Breast Cancer 2011; 11: 390-94. [IF: 2.375].
56. **Güth U.**, Myrick M.E., Schötzau A., Kilic N., Schmid S.M.; *Drug switch due to treatment-related adverse side affects in endocrine adjuvant therapy for breast cancer: how often and how often does it work?* Breast Cancer Res Treat 2011; 129: 799-807. [IF: 4.431].



57. Kilic N., Myrick M.E., Schmid S.M., **Güth U.**; *Eligibility, compliance and persistence of sequential therapy with aromatase inhibitors following 2-3 years of tamoxifen in endocrine adjuvant breast cancer therapy.* *Oncology* 2011; 81: 151-47. [IF: 2.267].
58. Kilic N., Gross M.W., **Güth U.**; *Behandlung des metastatischen Endometriumkarzinoms.* *info@onkologie* 2011; 6: 7-11.
59. Regan M.M., Neven P., Giobbie-Hurder A., Goldhirsch A., Ejlertsen B., Mauriac L., Forbes J.F., Smith I., Lang I., Wardley A., Rabaglio M., Price K.N., Gelber R.D., Coates A.S., Thürlimann B.; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). *Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up.* *Lancet Oncol* 2011; 12: 1101-08. [IF: 22.589].
60. Eichholzer M., Schmid S.M., Bovey F., Jordan P., Rohrmann S., Huang D.J., Rochlitz C., **Güth U.**; *Impact of overweight and obesity on postmenopausal breast cancer: analysis of 20-year data from Switzerland.* *Arch Gynecol Obstet* 2012; 285: 797-803. [IF: 1.330].
61. Myrick M.E., Schmid S.M., Kilic N., **Güth U.**; *Eligibility, compliance and persistence of extended adjuvant endocrine therapy for breast cancer.* *Acta Oncologica* 2012; 51: 247-53. [IF: 3.330].
62. **Güth U.**, Hadwin R.J., Schötzau A., McCormack M.; *Clinical outcomes and patterns of severe late toxicity in the era of chemo-radiation for cervical cancer.* *Arch Gynecol Obstet* 2012; 285: 1703-11. [IF: 1.330].
63. **Güth U.**, Myrick M.E., Kilic N., Eppenberger-Castori S., Schmid S.M.; *Compliance and persistence of endocrine adjuvant breast cancer therapy.* *Breast Cancer Res Treat* 2012; 131: 491-99. [IF: 4.469].
64. **Güth U.**, Myrick M.E., Viehl C.T., Weber W.P., Lardi A.M., Schmid S.M. *Increasing rates of contralateral prophylactic mastectomy – a trend made in USA?* *Eur J Surg Oncol* 2012; 38: 296-301. [IF: 2.614].
65. Schmid S.M., Eichholzer M., Bovey F., Myrick M.E., Schötzau A., **Güth U.**; *Impact of body mass index on compliance and persistence to adjuvant breast cancer therapy.* *Breast* 2012; 21: 487-92. [IF: 2.491].
66. Oeggerli M., Tian Y., Ruiz C., Wijker B., Sauter G., Obermann E., **Güth U.**, Zlobec I., Sausbier M., Kunzelmann K., Bubendorf L.; *Role of KCNMA1 in breast cancer.* *PLoS One* 2012; 7: e41664. [IF: 3.730].
67. **Güth U.** *Sentinellymphknotenbiopsie beim Mammakarzinom: Vertrauen in die Methode und Vermeidung unnötigen Aufwandes.* *Leading Opinions. Hämatologie & Onkologie* 2012 (1): 64-66; *JATROS. Medizin für die Frau* 2012 (1): 26-28; *Leading Opinions. Medizin für die Frau* 2012 (1): 24-26.
68. Chirgwin J., Sun J., Smith I., Price K.N., Thürlimann B., Ejlertsen B., Bonnefoi H., Regan M.M., Goldhirsch A., Coates A.S., et al.; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). *The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and those with chemotherapy-induced menopause.* *Breast Cancer Res Treat* 2012; 131: 295-306. [IF: 4.469].
69. Droeser R.A., Zlobec I., Kilic E., **Güth U.**, Heberer M., Spagnoli G.C., Oertli D., Tapia C.; *Differential pattern and prognostic significance of CD+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.* *BMC Cancer* 2012; 12: 134. [IF: 3.333].
70. **Güth U.**, Myrick M.E., Viehl C.T., Schmid S.M., Obermann E.C., Weber W.P.; *The post ACOSOG Z0011 era: does our new understanding of breast cancer really change clinical practice?* *Eur J Surg Oncol* 2012; 38: 645-50. [IF: 2.614].
71. Moffat R., de Geyter C., Myrick M.E., Schmid S.M., Sattmann C., Tschudin S., Kilic N., **Güth U.**; *Young women with breast cancer: how many are actually candidates for fertility preservation?* *Arch Gynecol Obstet* 2012; 286: 1521-27. [IF: 1.330].
72. **Güth U.** *Endometriose rezidivprophylaxe mit Dienogest (Visanne®) bei positivem Kinderwunsch.* *Elsevier Case Reports: Endometriose & Dienogest*; München: Elsevier., 2012: 4-5;



- b. *Prophylaxie des récidives de l'endométriose par diénoGEST (Vianne®) chez une patiente de 27 ans désirant avoir enfant.* Elsevier Case Reports: Endométriose & DiénoGEST; München: Elsevier., 2012: 4-5.
73. Lardi A.M., Myrick M.E., Haug M., Schaefer D.J., Bitzer J., Simmen U., **Güth U.**; *The option of delayed reconstructive surgery following mastectomy for invasive breast cancer: why do so few patients embrace this offer?* Eur J Surg Oncol 2012; 39: 36-43. [IF: 2.614].
74. **Güth U.**; *ACOSOG Z0011-Studie im klinischen Alltag: „practice changing trial“ oder ein zu gewagter Ansatz mit der Gefahr der Untertherapie?* JATROS. Medizin für die Frau 2012 (3): 58-60 / Leading Opinions. Medizin für die Frau 2012 (3): 22-24 / Leading Opinions. Hämatologie & Onkologie 2012 (4): 8-10.
75. Drosner R., Eppenberger-Castori U., **Güth U.**, Stadlmann S., Hirt C., Terraciano L., Singer G.; *High IL-17 positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma.* J Cancer Res Clin Oncol 2013; 139: 1295-1302. [IF: 3.009].
76. Vetter M., Huang D.J., Bosshard G., **Güth U.**; *Breast cancer in women 80 years of age and older: a comprehensive overview on an underreported entity.* Acta Oncol 2013; 52: 57-65. [IF: 3.710].
77. Eichholzer M., Huang D.J., Modlasiak A., Schmid S.M., Schötzau A., Rohrmann S., **Güth U.**; *Impact of body mass index on prognostically relevant breast cancer tumor characteristics.* Breast Care 2013; 8: 192-198. [IF: 0.911].
78. **Güth U.**, Schmid S.M., Eichholzer M.; *Entwicklung von Übergewicht und Adipositas beim Mammakarzinom und ihre Bedeutung für Diagnose und klinisches Management: Resultate der Basler Mammakarzinom-Datenbank 1990–2009.* Schweiz Rundsch Medizin Prax 2013; 102: 473-80.
79. **Güth U.**, Myrick M.E., Kandler C., Vetter M.; *The use of adjuvant endocrine breast cancer therapy in the oldest old.* Breast 2013; 22: 863-868. [IF: 2.581].
80. **Güth U.**, Wagner S., Huang D.J., Hess T.H.; *Pyoderma gangrenosum of the vaginal vault after vaginal hysterectomy: only the correct diagnosis of a rare entity can prevent long-term morbidity.* Arch Gynecol Obstet 2013; 288: 79-82. [IF: 1.279].
81. **Güth U.**, Vetter M., Huang D.J., Heinzelmann-Schwarz V.; *Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendations for staging imaging of node negative, hormonal receptor negative disease.* Ann Oncol 2013; 24: 555-557. [IF: 6.578].
82. **Güth U.**; *Staging auf Fernmetastasen bei operablem Mammakarzinom – Evidenz und Praxis.* Leading Opinions. Hämatologie & Onkologie 2012 (6): 60-63 / Leading Opinions. Medizin für die Frau 2013 (1): 6-9 / JATROS. Hämatologie & Onkologie 2013 (1): 64-67; JATROS. Medizin für die Frau 2013 (1): 20-23.
83. **Güth U.**; *Positiver Sentinel-Lymphknoten beim Mammakarzinom: wie weiter? Anmerkungen für den klinischen Alltag in der Schweiz.* Newsletter Schweizerischen Gesellschaft für Senologie 2013 (1): 5-9.
84. **Güth U.**, Magaton I., Huang D.J., Fisher R., Schötzau A., Vetter M.; *Primary and secondary distant metastatic breast cancer: two sides of the same coin.* Breast 2013; 23: 26-32. [IF: 2.581].
85. Amann E., Huang D.J., Weber W.P., Eppenberger-Castori S., Schmid S.M., Hess T.H., **Güth U.**; *Disease-related surgery in patients with distant metastatic breast cancer.* Eur J Surg Oncol 2013; 39: 1192-98. [IF: 2.892].
86. **Güth U.**; *Mammakarzinom bei der betagten Patientin.* Leading Opinions. Hämatologie & Onkologie 2013 (5): 62-70 / Leading Opinions. Medizin für die Frau 2013 (4): 28-35 / JATROS. Hämatologie & Onkologie 2013 (6): 80-87.
87. Schwab F.D., Bürki N., Huang D.J., Heinzelmann-Schwarz V., Schmid S.M., Vetter M., Schötzau A., **Güth U.**; *Impact of breast cancer family history on tumor detection and tumor size in women with newly-diagnosed with invasive breast cancer.* Fam Cancer 2014; 13: 99-107. [IF: 1.977].



88. Richard A., Rohrmann S., Mohler-Kuo M., Ajdacic-Gross V., Moffat R., **Güth U.**, Eichholzer M.; *Urinary phytoestrogens and major depression in perimenopausal US women: NHANES 2005-2008.* J Affect Dis 2014; 156: 200-205. [IF: 3.383].
89. Moffat R., Bergsma N., Sartorius G., Raggi A., **Güth U.**, de Geyter C.; *Does prior hysteroscopy affect pregnancy outcome in primigravid infertile women?* Am J Obstet Gynecol 2014; 211: 130:e1-6. [IF: 4.704].
90. Kann S., Schmid S.M., Eichholzer M., Huang D.J., Amann E., **Güth U.**; *The impact of overweight and obesity on breast cancer: data from Switzerland, so far a country little affected by the current global obesity epidemic.* Gland Surg 2014; 3: 181-197.
91. Moffat R., **Güth U.**; *Preserving fertility in patients undergoing treatment for breast cancer: current perspectives.* Breast Cancer-Targets and Therapy 2014; 6: 93-101.
92. Steinauer K., Gross M.W., Huang D.J., Eppenberger-Castori S., **Güth U.**; *Radiotherapy in patients with distant metastatic breast cancer.* Radiat Oncol 2014; 9: 126. [IF: 2.546].
93. Steinauer K., Huang D.J., Eppenberger-Castori S., Amann E., **Güth U.**; *Bone metastases in breast cancer: incidence, metastatic pattern and non-systemic locoregional therapy.* J Bone Oncol 2014; 3: 54-60. [IF: 1.205].
94. **Güth U.**; *Therapieverzicht und Heilung. Die „blinden Flecken“ des Onkologen beim metastasierten Mammakarzinom.* Leading Opinions, Hämatologie & Onkologie 2015 (1): 106-111.
95. Schwab F.D., Huang D.J., Schmid S.M., Schötzau A., **Güth U.**; *Self-detection and clinical breast examination: comparison of the two “classical” physical examination methods for the diagnosis of breast cancer.* Breast 2015; 24: 90-92. [IF: 2.740].
96. Schwab F.D., Kilic N., Huang D.J., Schmid S.M., Vetter M., Schötzau A., **Güth U.**; *Personal and family history and its impact on tumor detection and tumor size in newly diagnosed breast cancer.* Arch Gynecol Obstet 2015; 291: 1387-94. [IF: 1.680].
97. Soysal S.D., Kilic I.B., Regenbrecht C.R., Schneider S., Muenst S., Kilic N., **Güth U.**, Dietel M., Terraciano L.M., Kilic E.; *Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer.* Breast Cancer Res Treat 2015; 151: 709-15. [IF: 4.085].
98. **Güth U.**; *Das Mammakarzinom bei betagten Frauen. Eine Diskussion zu Versorgungsprinzipien zwischen Geriatrie, Hausarztmedizin und Onkologie.* Schweizer Zeitschrift für Onkologie 2015; 2: 9-14.
99. **Güth U.**, Arndt V., Stadlmann S., Huang D.J., Singer G.; *Epidemiology in ovarian carcinoma: lessons from autopsy.* Gynecol Oncol 2015; 138: 417-420. [IF: 4.198].
100. **Güth U.**, Huang D.J., Alder J., Moffat R.; *Family ties: young breast cancer patients and their children.* Swiss Med Wkly 2015; 145: w14163. [IF: 1.549]. / Extended abstract in: Swiss Medical Forum 2015; 15 (36): 806.
101. Richard A., Rohrmann S., Schmid S.M., Frey Tirri B., **Güth U.**, Eichholzer M.; *Lifestyle and health-related predictors of cervical cancer screening adherence in Switzerland.* Cancer Epidemiology 2015; 39: 870-876. [IF: 2.644].
102. **Güth U.**; *Assistierte Selbsttötung als ärztliche Aufgabe. Erfahrung mit rechtlichen und standesethischen Rahmenbedingungen in der Schweiz.* Leading Opinions, Hämatologie & Onkologie 2015 (6): 28-31; JATROS. Hämatologie & Onkologie 2015 (6): 26-30.
103. Eichholzer M., Richard A., Rohrmann S., Schmid S.M., **Güth U.**; *Overweight, obesity and breast cancer screening in Switzerland: results from the 2012 Swiss Health Survey.* Eur J Cancer Prev 2016; 25: 130-36. [IF: 2.556].
104. **Güth U.**, Huang D.J., Schötzau A., Schmid S.M. *The use of palliative endocrine therapy in patients with distant metastatic breast cancer: how often, how effective, how long?* Oncology 2016; 90: 1-9. [IF: 2.262].



105. **Güth U.**, Huang D.J., Bitzer J., Moffat R. *Unintended pregnancy during the first year after breast cancer diagnosis*. Eur J Contracept Reprod Health Care 2016; 21: 290-94. [IF: 1.627].
106. Drosler R., Mechera R., Däster S.R., Weixler B., Kraljevic M., Delko T., **Güth U.**, Stadlmann S., Terraciano L., Singer G.; *MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity*. BMC Cancer 2016; 16: 639. [IF: 3.288].
107. **Güth U.**; *Tumordetektion beim Mammakarzinom-Langzeitdaten aus der Schweiz*. Leading Opinions. Medizin für die Frau 2016 (3): 36-41. / *Leading Opinions*. Hämatologie & Onkologie 2016 (5): 66-71.
108. Eichholzer M., Richard A., Rohrmann S., Schmid S.M., Leo C., Huang D.J., **Güth U.**; *Characteristics associated with opportunistic and organized breast cancer screening attendance in Switzerland*. BMC Health Serv Res 2016; 16: 519. [IF: 1.827].
109. **Güth U.**, Huang D.J., Bitzer J., Frey Tirri B., Moffat R.; *Contraception counseling in young breast cancer patients: a practical needs assessment and a survey among medical oncologists*. Breast 2016; 30: 217-221. [IF: 2.801].
110. Vetter M., Fokas S., Biskup E., Schmid T., Schwab F., Schötzau A., **Güth U.**, Rochlitz C., Zanetti-Dällenbach R.; *Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience*. Oncotarget 2017; 8: 75617-26. [IF: 5.168].
111. Singer G., **Güth U.**; *Ovarialkarzinome – neue Aspekte in der Histopathologie., Molekularpathologie., Klinik und Therapie*. Ther Umsch 2017; 74: 181-89.
112. Ramser M., Eichelberger S., Däster S., Weixler B., Kraljevic M., Mechera R., Tampakis A., Delko T., **Güth U.**, Stadlmann S., Terraciano L., Drosler R., Singer G.; *High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy*. BMC Cancer 2018; 18: 425. [IF: 2.933].
113. Weber W.P., Tausch C., Hayoz S., Fehr M.K., Ribí K., Hawle H., Lupatsch J.E., Matter-Walstra K., Chiesa F., Dedes K.J., Berclaz G., Lelievre L., Hess T., **Güth U.**, Pioch V., Sarlos D., Leo C., Canonica C., Gabriel N., Zeindler J., Cassoly E., Andrieu C., Soysal S.D., Ruhstaller T., Fehr P.M., Knauer M.; *Impact of Surgical Sealing Patch on Lymphatic Drainage after Axillary Dissection for Breast Cancer. The SAKK 23/13 Multicenter Randomized Phase III Trial*. Ann Surg Oncol 2018; 25: 2632-2640. [IF: 3.681].
114. **Güth U.**, Breitenstein U.; *Neoadjuvante Chemotherapie beim Mammakarzinom. Neue Wege erweitern das Indikationsspektrum*. Leading Opinions. Hämatologie & Onkologie 2018 (7): 36-38.
115. Elfgen C., Papassotiropoulos B., Varga Z., Moskovszky L., Nap M., **Güth U.**, Baege A., Amann E., Chiesa F., Tausch C.; *Comparative analysis of confocal microscopy on fresh breast core needle biopsies and conventional histology*. Diagn Pathol 2019; 14: 58. [IF: 2.335]. / *Correction: Diagn Pathol* 2019; 14: 87.
116. Papassotiropoulos B., **Güth U.**, Chiesa F., Rageth C., Amann E., Baege A., Elfgen C., Varga Z., Moskovszky L., Endhardt K., Masser R., Tinguely M., Farhadi J., Lardi A., Dammann F., Diebold J., Qiyu L., Dubsky P., Tausch C.; *Prospective Evaluation of Residual Breast Tissue after SKIn- or Nipple-Sparing Mastectomy- Results of the SKINI-Trial*. Ann Surg Oncol 2019; 26: 1254-62. [IF: 4.061].
117. Elfgen C., **Güth U.**, Tausch C.; *Zweifel bei scheinbar gutartigem Brusttumor*. Swiss Medical Forum 2019; 19: 171-72.
118. Elfgen C., Varga Z., Reeve K., Moskovszky L., Bjelic-Radisic V., Tausch C.J., **Güth U.**; *The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay*. Breast Cancer Res Treat 2019; 177: 67-75. [IF: 3.831].
119. **Güth U.**, Elfgen C., Montagna G., Schmid S.M.; *Long-term survival and cure in distant metastatic breast cancer*. Oncology 2019; 97: 82-93. [IF: 2.642].
120. Elfgen C., Montagna G., Schmid S.M., Bierbauer W., **Güth U.**; *Non-compliance with palliative systemic therapy in patients with distant metastatic breast cancer: a blind spot for oncologists?* Breast Cancer Res Treat 2019; 176: 469-76. [IF: 3.831].



121. Elfgen C., Reeve K., Moskovszky L., **Güth U.**, Bjelic-Radiscic V., Fleisch M., Tausch C.J., Varga Z.; *Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.* J Cancer Res Clin Oncol 2019; 145: 2051-2059. [IF: 3.656].
122. Elfgen C., Schmid SM., Tausch C.J., Montagna G., **Güth U.**; *Radiological staging for distant metastases in breast cancer patients with confirmed local and/or locoregional recurrence: how useful are current guideline recommendations?* Ann Surg Oncol 2019; 26: 3455-61. [IF: 4.061]. / Editorial: Sacchini V. *Restaging patients with locoregional relapse: is there any benefit?* Ann Surg Oncol 2019; 26: 3415-17
123. **Güth U.**; *ASO Author Reflections: Routine radiological staging of distant metastases must be recommended as a binding guideline after diagnosis of local breast cancer recurrence.* Ann Surg Oncol 2019; 26: 3462-63. [IF: 4.061].
124. Papassotiropoulos B., **Güth U.**, Dubsky P., Tausch C.; *ASO Author Reflections: A call for surgeon experience and surgical radicality to prevent breast tissue after skin- and nipple sparing mastectomy.* Ann Surg Oncol 2019; 26 (Suppl 3): S694-95. [IF: 4.061].
125. Montagna G., Schneeberger AR., Rossi L., Reina H., Schwab F., Schoetzau A., Eichholzer M., Pagani O., Weber W.P., Kurzeder C., **Güth U.**, Huber C.G.; *The impact of depression on adherence to organized and opportunistic breast cancer screening in Switzerland.* Eur J Cancer Prev 2020; 29: 53-59. [IF: 2.497].
126. Posabella A., Köhn P., Lalos A., Wilhelm A., Mechera R., Soysal S., Muenst S., **Güth U.**, Stadlmann S., Terraciano L., Drosler RA., Zeindler J., Singer G.; *High density of CD66b in primary high-grade ovarian cancer independently predicts response to chemotherapy.* J Cancer Res Clin Oncol 2020; 146: 127-136. [IF: 4.553].
127. Müller M., **Güth U.**, Varga Z., Reeve K., Bjelic-Radiscic V., Fleisch M., Tausch C.J., Elfgen C.; *Clinical imaging of the heterogeneous group of triple-negative breast cancer.* Anticancer Res 2020; 40: 2125-2131. [IF: 2.480].
128. Elfgen C., Montagna G., Schmid S.M., Bierbauer W., **Güth U.**; *Metastatic breast cancer as a chronic disease: evidence-based data on a theoretical concept.* Breast Care 2020; 15: 281-88. [IF: 2.860].
129. Elfgen C., **Güth U.**, Gruber G., Birrer S., Bjelic-Radiscic V., Fleisch M., Tausch C.J.; *Breast-conserving therapy with intraoperative radiotherapy in recurrent breast cancer: the patient's perspective.* Breast Cancer 2020; 27: 1107-13. [IF: 4.239].
Akrida I., Argentou Ml. *Letter to the editor: comment on 'Breast-conserving therapy with intraoperative radiotherapy in recurrent breast cancer: the patient's perspective' by Elfgen et al.* Breast Cancer 2020; 27: 1205-06.
130. **Güth U.**, Borovecki A., Amann E., Rechsteiner M., Tinguely M.; *Pleomorphic lobular breast carcinoma with osteoclast like giant cells in the era of genomic testing.* Current Problems in Cancer: Case Reports 2020; 1: 100008.
131. Elfgen C., Baumgartner S., Varga Z., Reeve K., Tausch C.J., Bjelic-Radiscic V., Fleisch M., **Güth U.** *Diagnostic delay in moderately/poorly differentiated breast cancer types.* Eur J Cancer Prev 2021 Apr 23. Online ahead of print. [IF: 2.497].
132. Elfgen C., Tausch C.J., Rodewald A.K., **Güth U.**, Rageth C., Bjelic-Radiscic V., Fleisch M., Kurtz C., Diaz J.G., Varga Z.; *Clinical and histopathological characteristics of classical type of lobular neoplasia of the breast as a decision-making aid.* Breast Care 2021; Online ahead of print. [IF: 2.860].

Buchbeitrag

Güth U.; *Die Universitäts-Frauenklinik Basel im Spiegel der vergangenen 50 Jahre.* In: 550 Jahre Universität Basel. Unigeschichts-Website der Universität Basel zur 550-Jahr-Feier. Online unter: www.unigeschichte.unibas.ch/fakultaeten-und-faecher/medizinische-fakultaet/juengste-entwicklungen-der-medizinischen-fakultaet/frauenklinik.html



bzw. unter:

www.unigeschichte.unibas.ch/cms/upload/FaecherUndFakultaeten/Downloads/Gueth_UFK.pdf

Fortbildung

Kollegium Brustkrebs. Modul 2. Zürich., 2012/2015. **Güth U.**; *Brustkrebs bei älteren Patientinnen. Nachsorge und Rezidivtherapie*. Kommentierte Powerpoint-Slides.

Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe (SGGG) Gynécologie Suisse. E-learning Portal: <http://egone.ch/index.html>. **Güth U.**; *Mammakarzinom: Ausbreitung und Prävention (G10c). Breast cancer: spread and prevention*

Lehrbücher/Lehr-DVDs

Postgraduate Training and Research in Reproductive Health M. Runge, editor

Schiesser M., **Güth U.**; *Module 5: High Risk Pregnancy I*. Freiburg: Verlag der Universitäts-Frauenklinik Freiburg, 2004.

Schiesser M., **Güth U.**; *Module 5: High Risk Pregnancy I*. Freiburg., 2009. DVD: Powerpoint-Präsentation, 310 slides.

Schiesser M., **Güth U.**; *Module 6: High Risk Pregnancy II*. Freiburg: Verlag der Universitäts-Frauenklinik Freiburg, 2004.

Schiesser M., **Güth U.**; *Module 6: High Risk Pregnancy II*. Freiburg, 2009. DVD: Powerpoint-Präsentationen, 251 slides.

Zürich., September 2021